Two thirds of drug launches fail to hit first year sales forecasts. One in ten launches between 2020 and 2024 cleared 100 million dollars in year one revenue, half the rate of the previous five years. By every measurable indicator, the industry is getting worse at commercializing the science it spends a decade developing.
The default explanation is that molecules are not differentiated enough, the trials are noisier, or the market is more crowded. None of those holds up when you actually look at the data.
The 49 vs 67 Percent Commitment Gap
ZS Associates ran a retrospective on 340 brand launches between 2008 and 2025. The headline finding is the one most pharma boards have not internalized yet.
Clinical differentiation alone produces a 49 percent overperformance rate. Clinical differentiation plus manufacturer commitment produces 67 percent.
Eighteen points. That is the entire commercial opportunity, and it has almost nothing to do with the molecule.
Commitment, in their definition, is the boring stuff. Multi year investment in commercialization before approval. Market access engaged during Phase 2 trial design. Manufacturing capacity built ahead of demand. A single accountable launch leader instead of a committee. Patient support funded before launch instead of bolted on after.
These are not strategy problems. They are organizational discipline problems. Every one of them is decidable two years before launch. None of them is decidable in the first quarter after approval.
What This Looks Like in Real Launches
The case studies make this concrete. Lilly invested 5.3 billion dollars in manufacturing capacity for Mounjaro before demand fully materialized. Novo Nordisk did not, and lost global category leadership it had once owned outright. Same therapeutic area, same payer environment, same year. Different operating system around the molecule.
Mounjaro and Zepbound combined hit 22.9 billion dollars in 2025 sales, up 99 percent year over year. The trajectory was the steepest sustained commercial ramp in pharmaceutical history. It was not primarily a story about the molecule. Tirzepatide was clinically differentiated but only by modest margins versus semaglutide on weight loss endpoints. It was a story about the commercial system Lilly built around the molecule, 24 to 36 months before launch.
On the other end, Aduhelm launched at 56,000 dollars a year with no clear CMS coverage decision, against the recommendation of ten of eleven advisory committee members. First year sales hit 4.6 million. The molecule was controversial, but the launch failure was not the molecule. It was the commercial system pretending the controversy did not exist.
Why Most Companies Cannot Close the 18 Point Gap
The honest reason is sequencing. The HCP demand forecast gets built years before launch by the strategy team. The market access forecast gets built months before launch by a different team with different vendors and different timelines. By the time the second number arrives, the first is locked. Capital is allocated. The sales team is being hired.
When the two numbers are close, you have a favorable launch environment. When the gap is wide, you have a board meeting twelve months from now you cannot prepare for, because the problem was solvable two years ago.
What Companies in the 67 Percent Group Actually Do
The patterns are not subtle. The companies that win consistently are not the ones with better creative agencies or sharper messaging. They are the ones who started commercial work 30 plus months before launch, sized patient populations honestly instead of optimistically, embedded payer evidence into Phase 2 trial design, built manufacturing capacity before demand materialized, and concentrated launch accountability in a single named leader instead of a committee.
Every one of these is observable from outside. Every one of them is decidable years before launch. None of them is decidable from a marketing budget conversation in Q4.
The Implication
Launch failure is mostly not a launch problem. It is a pre approval discipline problem dressed up as a marketing one.
If your launch calendar starts at 12 months before approval, you are already in the 49 percent group. The 67 percent group is running 36 month launch calendars, and the gap between the two cohorts is widening every year as the commercial environment gets harder.
That is the entire game.
